GLP-2 TRZ Pen 40mg- Adjustable Dose

GLP-2 TRZ is a dual incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) receptors. The dual GIP/GLP-1 mechanism that distinguishes this compound class from single receptor GLP-1 agonists and from triple receptor agonists. F40 Biotech’s 40mg adjustable dose pen delivers this dual incretin agonist in a prefilled pen system with dose adjustment capability, introducing a distinct delivery format to CSD’s GLP-2 TRZ range alongside the existing lyophilized vial presentations, combining administration convenience with the dosing flexibility typically associated with reconstitute preparations.

The adjustable dose pen format serves a specific research purpose within CSD’s dual incretin agonist range. The GLP-2 TZ 15mg, GLP-2 TRZ 20mg, and GLP-2 TRZ 30mg lyophilized vials provide reconstitution controlled formats suited to in vitro applications and protocols requiring precise solution concentration preparation. The adjustable dose pen eliminates reconstitution preparation entirely while maintaining dose titration capability. This allows researchers to dial precise incremental doses from the 40mg pen supply across the protocol timeline without preparation variability between administrations. At 40mg total this pen provides a higher compound capacity than any single lyophilized vial in the GLP-2 TRZ range, supporting extended administration timelines from a single pen unit.

The dual GLP-1 and GIP receptor co activation mechanism remains consistent across all GLP-2 TRZ presentations regardless of format. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic effects and bone turnover research dimensions. The combined receptor profile producing a synergistic incretin response that has made dual incretin agonist compounds among the most actively researched peptide classes in contemporary metabolic science. Within CSD’s broader incretin family, the GLP-2 TRZ pen sits between the pure GLP-1 selectivity of the Semaglutide pen and the triple receptor complexity of the GLP-3 RTA adjustable dose pens in terms of receptor pathway coverage.

F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s GLP-2 TRZ pen meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside GLP-1 agonist compounds and triple incretin agonists in comparative incretin pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.